...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >DESIGN, SYNTHESIS, AND CYTOTOXICITY EVALUATION OF NOVEL OPEN-CHAIN ANALOGUES OF ANTIMYCIN A 3 AS POTENTIAL ANTI-COLORECTAL CANCER AGENTS
【24h】

DESIGN, SYNTHESIS, AND CYTOTOXICITY EVALUATION OF NOVEL OPEN-CHAIN ANALOGUES OF ANTIMYCIN A 3 AS POTENTIAL ANTI-COLORECTAL CANCER AGENTS

机译:新型抗菌素A 3作为可能的抗结肠直肠癌药物的开链类似物的设计,合成和细胞毒性评估

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: Colorectal cancer is the third most common diagnosed cancer in the world. The aim of this work was to design, to synthesize, and to evaluate the novel open-chain analogues of antimycin A 3 as highly potent anti-colorectal cancer agents. Methods: Our analogue synthesis was designed by modifying the nine-membered dilactone moiety of antimycin A with a simple open-chain moiety, as well as introducing the stereocenter, and the hydroxyl groups on the side chain of the ester group. The synthesis was conducted through a sequence of reactions from Boc-L-threonine by esterification, amidation, and sharpless asymmetric dihydroxylation. After completion the synthesis, cytotoxicities of the analogues were evaluated as inhibitors of colorectal HCT-116 cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation assay. Results: Novel open-chain analogues of antimycin A were successfully synthesized in a good yield. The analogues exhibited a greater anticancer activity against colorectal HCT-116 cells than the original antimycin A 3 with 50% inhibitory concentrations ranging of 35.0-47.0 μM. The results indicated that the presence of stereocenter and a hydroxylated open-chain moiety in the analogues were successfully improved its anti-colorectal cancer activity. 3 Conclusion: Our results clearly demonstrate that the opened-chain analogues of antimycin A as a promising candidates of new anti-colorectal cancer agents.
机译:目的:大肠癌是世界上第三大被诊断出的癌症。这项工作的目的是设计,合成和评估抗霉素A 3作为强效抗结直肠癌药物的新型开链类似物。方法:我们的类似物合成是通过用简单的开链部分修饰抗霉素A的九元双内酯部分,并引入立体中心和酯基侧链上的羟基而设计的。通过Boc-L-苏氨酸的一系列反应,通过酯化,酰胺化和尖锐的不对称二羟基化反应进行合成。完成合成后,通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四溴甲烷细胞增殖试验评估类似物作为结肠直肠HCT-116细胞抑制剂的细胞毒性。结果:成功合成了抗霉素A的新型开链类似物。与原始抗霉素A 3相比,该类似物对结肠直肠HCT-116细胞表现出更大的抗癌活性,抑制浓度为35.0-47.0μM,为50%。结果表明,类似物中立体中心和羟基化的开链部分的存在成功地改善了其抗结肠直肠癌的活性。 3结论:我们的结果清楚地表明,抗霉素A的开链类似物是新型抗结直肠癌药物的有希望的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号